Table. 2.

Strategies for CMV prevention in CMV D+/R– transplant recipients

Characteristic Kidney (n=31) Liver (n=25) Heart (n=8) Lung (n=8)
None 3 (10) 2 (8) 0 0
Prophylaxis 10 (32) 7 (28) 5 (63) 3 (38)
Valacyclovir (oral) 3 (10) 0 0 0
Valganciclovir (oral) 7 (23) 7 (28) 5 (63) 3 (38)
Duration of prophylaxis (mo) 3 (2‒6) 3 (1‒3) 3 (1‒3) 6 (3‒6)
Prophylaxis+preemptive strategy 12 (39) 7 (28) 3 (38) 5 (63)
Valacyclovir (oral)+qPCR monitoring 4 (13) 0 0 0
Ganciclovir (intravenous)+qPCR monitoring 0 1 (4) 0 0
Valganciclovir (oral)+qPCR monitoring 7 (23) 6 (24) 2 (25) 5 (63)
Cut-off value of qPCR for preemptive therapy initiation (copies or IU/mL) 1,000 (34.5‒10,000) 1,000 (34.5‒10,000) 10,000 (10,000–10,000) 3,500 (1,000–10,000)
Valganciclovir (oral)+antigenemia monitoring 1 (3) 0 1 (13) 0
Cut-off value of antigenemia for preemptive therapy initiation (no./200,000 WBC) 25 0 1 0
Duration of prophylaxis (mo) 3 (3‒6) 2 (0.5‒6) 3 (3‒3) 6 (3‒6)
Duration of preemptive monitoring (mo) 8 (5‒24) 9 (1‒12) 12 (6‒12) 12 (6‒48)
Preemptive strategy 6 (19) 9 (36) 0 0
Preemptive strategy based on qPCR 6 (19) 6 (24) 0 0
Cut-off value of qPCR for preemptive therapy initiation (copies or IU/mL) 1,000 (34.5‒1,000) 1,000 (500‒10,000) 0 0
Preemptive strategy based on antigenemia 0 3 (12) 0 0
Cut-off value of antigenemia for preemptive therapy initiation (no./200,000 WBC) 0 4 (1‒5) 0 0
Duration of preemptive monitoring (mo) 12 (3‒12) 3 (1‒12) 0 0

Values are presented as number (%) or median (range).

CMV, cytomegalovirus; qPCR, quantitative polymerase chain reaction; WBC, white blood cell.

Korean J Transplant 2022;36:212~220 https://doi.org/10.4285/kjt.22.0036
© Korean Journal of Transplantation